A New Dawn in HIV Treatment: FDA Approves Sunlenca (Lenacapavir)
In a significant development on December 22, 2022, the U.S. Food and Drug Administration (FDA) approved a new antiretroviral medication, Sunlenca (lenacapavir), for adult patients living with human immunodeficiency virus type 1 (HIV-1). This approval marks an important moment in the evolution of HIV treatment, introducing a novel class of drugs known as capsid inhibitors […]
A New Dawn in HIV Treatment: FDA Approves Sunlenca (Lenacapavir) Read More »